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S U M M A R Y
Objectives: The identiﬁcation of the speciﬁc pathogen responsible for a respiratory infection in patients
with hematological malignancies (HM) would ensure relevant treatment and prevent toxicity associated
with anti-infective therapy. This large-scale study aimed to explore the clinical impact of ﬁberoptic
bronchoscopy with bronchoalveolar lavage (FOB-BAL) in conjunction with molecular analysis on the
diagnosis and management of respiratory infections in hemato-oncological patients.
Methods: All consecutive patients with HM and pulmonary inﬁltrates, who underwent FOB-BAL
between January 2008 and January 2013, were included in the analysis. Clinical characteristics, FOB-BAL
results, and treatment adjustments were recorded, and factors predicting a positive BAL were assessed.
Results: Four hundred and twenty-ﬁve FOB-BAL procedures were analyzed. BAL revealed a speciﬁc
diagnosis in 219 (51.5%) patients, 208 of them with a pulmonary infection. Infectious etiological agents
found were mainly Aspergillus spp (n = 142), bacterial species (n = 44), and Pneumocystis jirovecii (n = 34).
Multivariate analysis showed that a lymphoproliferative disease, 2 symptoms (dyspnea/cough/
hemoptysis/pleuritic pain), and less than 4 days between symptom appearance and FOB-BAL, predicted a
positive FOB-BAL result. BAL results prompted a treatment modiﬁcation in 48% of subjects.
Conclusions: FOB-BAL in conjunction with molecular assays is efﬁcient in the rapid detection of life-
threatening infections, allowing for adjustment of anti-infective therapy, which may result in better
outcomes and reduce treatment-related toxicity.
 2016 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
Contents lists available at ScienceDirect
International Journal of Infectious Diseases
jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Respiratory complications are recorded in about 60% of patients
with hematological malignancies (HM) treated with chemothera-
py and in 80% of patients undergoing allogeneic stem cell
transplantation.1 Infections appear to be responsible for the* Corresponding author. Tel.: +972 4 854 2648; fax: +972 4 854 2721.
E-mail address: e_hardak@rambam.health.gov.il (E. Hardak).
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).majority of these events. Important differential diagnoses include
lung involvement by the underlying malignancy, capillary leak
syndrome, and lesions caused by chemotherapy or radiation.2,3
Establishing the speciﬁc cause of pulmonary inﬁltrates would
enable the prompt delivery of a speciﬁc therapy. In cases of
pulmonary infection, identiﬁcation of the speciﬁc etiology would
allow the early administration of appropriate therapy, which could
improve the outcomes and reduce mortality in this patient
population.4–6 Non-invasive diagnostic tests, such as sputum
cultures, blood cultures, and serological tests, have limited
diagnostic value in this setting. While open lung biopsy has theociety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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bronchoscopy with bronchoalveolar lavage (FOB-BAL) enables the
selective collection of lung ﬂuid so that a speciﬁc diagnosis of
infectious, malignant, or hemorrhagic disorders can be achieved
with relative ease. As patients with respiratory distress and
coagulation disorders can also withstand bronchoscopy, it has
become the diagnostic procedure of choice in these individuals.9–13
Previous studies,12–18 including one conducted at our center
Rambam Health Care campus,15 investigating the efﬁcacy of FOB-
BAL for the diagnosis of pulmonary inﬁltrates in patients with HM,
have reported a variable diagnostic yield, especially for infectious
agents, ranging between 20% and 60%. The introduction of
molecular methods has been suggested to improve the diagnostic
efﬁcacy of FOB-BAL, particularly in detecting fungal, viral, and
Pneumocystis jirovecii infections,19–23 and to promote the tailoring
of anti-infectious therapy.
The aim of the present study was to explore the diagnostic yield
of FOB-BAL, in the era of molecular techniques, in hemato-
oncological patients presenting with pulmonary inﬁltrates.
2. Materials and methods
This study was approved by the Institutional Review Board of
the Rambam Health Care Campus (approval number RMB 0416-
12). All consecutive patients with HM and pulmonary inﬁltrates,
who underwent diagnostic FOB-BAL between January 2008 and
January 2013, were included in the study.
Bronchoscopies were performed using a ﬂexible ﬁberoptic
bronchoscope (Olympus). Procedures were carried out through the
nasal or oral cavity following sedation (5 mg intravenous mid-
azolam) and local anesthesia (lidocaine 2%) and were supported
with cardiopulmonary monitoring (continuous assessment of
pulse rate, blood pressure, and oxygen saturation). Patients with
a platelet count lower than 20  109/l received 6 units of platelets
within an hour prior to the procedure.
The patients’ electronic medical records were reviewed for
demographic characteristics, underlying hematological illnesses
(type of HM, type of hematopoietic stem cell transplantation
(HSCT), graft-versus-host disease (GVHD), neutropenic status),
chronic comorbidities (ischemic heart disease, diabetes mellitus,
hypertension, chronic lung disease, liver disease, and renal
disease), clinical characteristics of the respiratory event (fever,
cough, hemoptysis, chest pain, oxygen saturation, respiratory
support), chest imaging ﬁndings, and in-hospital mortality.
Antimicrobial therapy before and after diagnostic bronchoscopy
results was also recorded.
The etiological diagnosis of pulmonary infection was estab-
lished using diagnostic FOB-BAL along with supportive blood and
urine microbiological and serological analysis. BAL ﬂuid laboratory
analysis included the following: cytological staining for the
detection of fungal elements, P. jirovecii bodies, and viral inclusion
bodies in alveolar cells; bacterial cultures with speciﬁc growth
media for Mycobacterium spp and Legionella spp; fungal cultures;
viral cultures for herpes simplex virus (HSV) and cytomegalovirus
(CMV); PCR for the detection of Aspergillus spp, Legionella spp, P.
jirovecii, HSV, CMV, and respiratory viruses DNA. Galactomannan
antigen was measured in BAL and serum.
2.1. Deﬁnitions
Bacterial pneumonia was deﬁned in the presence of a positive
BAL culture for any Mycobacterium, Legionella, Nocardia, or
Actinomyces species; a positive PCR for Legionella spp or Mycobac-
terium spp DNA; a positive BAL culture for pathogenic bacteria
(Gram-negative, pneumococci) in the amount of >105 CFU/ml and
in the absence of another pathogen. For any other bacterial species,a positive blood culture was required, along with a positive BAL
culture.
Fungal pneumonia was deﬁned in the presence of a positive BAL
culture for any mold or rare yeast. Invasive pulmonary aspergillo-
sis (IPA) was deﬁned according to the modiﬁed European
Organisation for Research and Treatment of Cancer (EORTC)
criteria, accepting a positive galactomannan antigen in blood or
BAL samples. A positive PCR in BAL for the detection of Aspergillus
spp DNA in the presence of a typical chest computed tomography
(CT) scan was also considered diagnostic.24–26 Candida spp was
considered an etiologic agent only with a concomitant positive
blood culture.
Viral pneumonia was deﬁned in the presence of a positive BAL
culture and/or PCR for any respiratory virus. For HSV and CMV
viruses, there was an additional requirement for the presence of
characteristic viral inclusion bodies in the alveolar cells, as
detected by direct staining.27
P. jirovecii pneumonia (PJP) was deﬁned in the presence of
P. jirovecii bodies visualized on silver/methenamine stains and/or
P. jirovecii DNA detected by PCR in BAL ﬂuid obtained from patients
with established predisposing factors and typical clinical and
imaging features in a high-resolution CT scan.28
A polymicrobial pulmonary infection was deﬁned when two or
more infectious agents were indentiﬁed based on the above
criteria. The diagnostic yield of FOB-BAL was considered the
proportion of cases with a speciﬁc diagnosis. A change in patient
management was deﬁned as the addition or subtraction of any
anti-infective agent after receiving FOB-BAL results. The anti-
infective prophylaxis policy at the center during the study period
included the following: ciproﬂoxacin antibacterial prophylaxis
during neutropenia; ﬂuconazole antifungal prophylaxis during
neutropenia and for 100 days in allogeneic HSCT recipients (no
anti-mold prophylaxis was administered); trimethoprim–sulfa-
methoxazole anti-P. jirovecii prophylaxis in allogeneic HSCT
recipients.
2.2. Diagnostic PCR reactions
Aspergillus spp DNA was detected using a two-step (nested) PCR
that speciﬁcally ampliﬁes the region of the 18S ribosomal RNA
gene, which is highly conserved in Aspergillus species. The test was
performed on extracted DNA using a QIAamp DNA Mini Kit
(Qiagen, Hilden, Germany).29
P. jirovecii PCR was used to detect three distinct genes of the
pathogen: the mitochondrial large subunit rRNA gene, the major
surface glycoprotein,30 and the T1–T2 region of the large subunit
ribosomal RNA gene,31 aiming to decrease false-positivity. PCR was
considered positive if at least two out of the three genes produced a
positive signal when ampliﬁed.
Legionella DNA was detected using Legionella ATCC 33152-
speciﬁc primers that amplify a portion of the 16S rRNA gene.32 The
primers Leg F2 (50-GAGGCAGCAGTGGGGAAT) and Leg R2 (50-
CCCAGGCGGTCAACTTAT) were used.
2.3. Statistical analysis
Descriptive statistics included the calculation of the median,
standard deviation, and frequency of the analyzed parameters. In
cases where the patient underwent more than one bronchoscopy,
each procedure was counted individually. Univariate analysis was
performed using binary logistic regression, calculating the odds
ratios (OR) with 95% conﬁdence intervals (CI) and p-values.
Multivariable stepwise logistic regression analysis was used to
assess the relationship between patient characteristics and
positive bronchoscopy. Variables selected for multivariate analysis
were those found to be signiﬁcant in the univariate analysis. Two-
Table 2
Distribution of the etiological agents of pulmonary infections in patients
with hematological malignancies
Pathogens recovered from BAL samples Number
Total number of pathogens 259
Fungi, total 188
Molds 147
Aspergillus spp 142
Fusarium 3
Zygomycetes 2
Yeasts 7
Cryptococcus 1
Candidaa 2
Rare yeastsb 4
Pneumocystis jirovecii 34
Bacteria, total 44
Enterobacteriaceae 10
Pseudomonas aeruginosa 10
Stenotrophomonas maltophilia 6
Acinetobacter 2
Legionella pneumophila 10
Nocardia cyriacigeorgica 2
Otherc 4
Viruses, total 27
Respiratory viruses 23
Inﬂuenza 11
Parainﬂuenza 5
Respiratory syncytial virus 3
Human metapneumovirus 2
Adenovirus 2
Herpes viruses 4
HSV 2
CMV 2
BAL, bronchoalveolar lavage; HSV, herpes simplex virus; CMV, cytomega-
lovirus.
a These two patients had catheter-related candidemia with multiple
Candida pulmonary septic emboli.
b Scopulariopsis (n = 2); Geotrichum capitatum (n = 2).
c Chrysiomonas (n = 1), Streptococcus pneumoniae (n = 1), undeﬁned
Gram-negative bacteria (n = 2) .
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signiﬁcant.
All statistical analyses were performed using IBM SPSS Statistics
for Windows, version 21.0 software (IBM Corp., Armonk, NY, USA).
3. Results
Four hundred and twenty-ﬁve FOB-BALs were performed and
included in the analysis. All except 13 procedures were performed
as part of the investigation of independent respiratory events. The
latter 13 procedures were performed in patients with unexplained
progressing respiratory infections in whom a prior FOB-BAL had
been non-informative. The median age at the time of FOB-BAL was
57 years (range 18–88 years). Forty-one percent (n = 175) of FOB-
BALs were performed in patients with lymphoproliferative
disorders (chronic lymphocytic leukemia (CLL), lymphoma,
multiple myeloma (MM)) and 55% (n = 235) in patients with acute
leukemia. Table 1 presents the characteristics of the patients who
underwent FOB-BAL in this study.
3.1. Clinical features and treatment of the respiratory events
examined by FOB-BAL
Fever was the most common clinical symptom, recorded in 89%
of cases, followed by dyspnea (49%) and cough (36%). In 385 cases
(90.5%), high-resolution CT had been performed prior to FOB-BAL.
Two hundred and seventy-seven (65%) scans showed diffuse
bilateral inﬁltrates and 148 demonstrated a unilateral involve-
ment.
Anti-infective agents were administered preemptively in
399 cases, before or immediately after the performance of FOB-
BAL. These included broad-spectrum antibiotics (n = 382, 90%),
antifungals (n = 303, 71%), antivirals (n = 34, 8%), and anti-P.
jirovecii agents (n = 87, 20%).
3.2. FOB-BAL results
FOB-BAL provided a speciﬁc diagnosis in 51.5% of cases. FOB-
BAL revealed 11 cases of non-infectious etiology (10 bleeding,
1 lymphoma) and 208 (48.9%) cases were diagnosed with aTable 1
Baseline characteristics of patients who underwent FOB-BALa
Characteristics
Total number of FOB-BAL procedures, n (%) 425 (100%)
Age, years, median (range) 57 (18–88)
Sex, n (%)
Male 242 (57%)
Female 183 (43%)
Hematological malignancy, n (%)
Acute leukemia 235 (55%)
Lymphoproliferative disorder (CLL, lymphoma, MM) 175 (41%)
Other 15 (4%)
Co-morbidities, n (%)
IHD 93 (22%)
Diabetes mellitus 20 (5%)
Chronic lung disease 15 (4%)
Prior transplanta
Allo SCT 108 (25%)
Auto SCT 69 (16%)
GVHD 65 (15%)
Concurrent neutropenia (<0.5  109 cells/l ) 197 (46%)
Thrombocytopenia <20  109/l prior to FOB-BAL 64 (15%)
FOB-BAL, ﬁberoptic bronchoscopy with bronchoalveolar lavage; CLL, chronic
lymphocytic leukemia; MM, multiple myeloma; IHD, ischemic heart disease; Allo
SCT, allogeneic stem cell transplantation; Auto SCT, autologous stem cell
transplantation; GVHD, graft-versus-host disease.
a The characteristics are presented per procedure.pulmonary infection. A polymicrobial etiology (two or more
infectious agents) was established in 45 (21%) of them. Two
hundred and six (48.5%) procedures were non-diagnostic.
The pathogens detected are listed in Table 2. The most
common infectious diagnosis was fungal pneumonia (154/208,
74%), with Aspergillus spp being the fungal pathogen in 142
(92%) of them. Bacterial pneumonia was diagnosed in 44/208
(21%) cases, caused by Gram-negative aerobic bacilli in 31
(70%) and Legionella pneumophila in 10 (23%) of them. PJP
was diagnosed in 34/208 (16%) episodes and viral pneumonia in
27/208 (13%) cases, most of them (n = 21, 77%) caused by
respiratory viruses.
The diagnosis of IPA was ‘probable’ (according to the criteria of
the EORTC/MSG Consensus Group 2008) in 115 cases and
‘possible’ in 27 cases (all possible IPA cases were supported by
positive Aspergillus PCR in BAL). Among the 115 cases of probable
IPA, 53 also had a positive PCR for Aspergillus DNA in BAL. Patients
with possible IPA, based on the EORTC criteria (and treated for
IPA), who had a negative PCR for Aspergillus DNA, were included
in the group of 206 patients with a non-diagnostic FOB-BAL. The
diagnosis of PJP was conﬁrmed by PCR in 31/34 (91%) cases and in
the remaining three cases the organism was also visualized by
direct staining. Respiratory viral pneumonia was also diagnosed
by PCR.
Among the 45 patients with a polymicrobial infection, 39 had a
pulmonary infection caused by two microorganisms and six had an
infection caused by three microorganisms. Aspergillus spp was the
most common co-pathogen in the group of polymicrobial
pulmonary infection (39/45, 87%).
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Univariate analysis (Table 3) found the diagnosis of a
lymphoproliferative disease to be associated with a high likelihood
of obtaining a positive FOB-BAL result. A shorter period between
the appearance of clinical symptoms and FOB-BAL indicated a
greater chance of obtaining a positive result. The more respiratory
symptoms were present at the time of FOB-BAL performance, the
higher the likelihood of a positive result. There was an association
between prolonged neutropenia (mainly occurring in the context
of anti-leukemic therapy or stem cell transplantation) and the
detection of Aspergillus in BAL, and between the existence of
profound lymphopenia and the detection of P. jirovecii.
Multivariate analysis conﬁrmed a lymphoproliferative disease
(OR 1.67, 95% CI 1.2–2.5, p = 0.012), 2 respiratory symptoms (OR
2.76, 95% CI 1.2–6.2, p = 0.015), and a shorter time (<4 days vs. >4
days) between the ﬁrst symptom and FOB-BAL (OR 0.61, 95% CI
0.38–0.98, p = 0.044) to be associated with a higher likelihood of
obtaining a positive FOB-BAL result (Supplementary Material
Table S1 summarizes the characteristics of patients with a positive
vs. a negative BAL result).
3.4. The impact of FOB-BAL results on the management of respiratory
infection
As mentioned above, in 94% (n = 399) of cases, the patient had
received an antibacterial and/or antifungal therapy based on
clinical and imaging ﬁndings prior to the FOB-BAL being
performed.
FOB-BAL results prompted a treatment modiﬁcation (either
cessation or the addition of anti-infectious agents) in 48% (n = 205)
of cases. The therapy was adjusted in 65% (n = 141) of cases where
the FOB-BAL result was positive and in 31% (n = 64) of cases of a
negative test. FOB-BAL results led to the initiation of a new
treatment in 89 of 141 cases, including antibacterial (n = 16),
antifungal (n = 43), anti-P. jirovecii (n = 15), and antiviral therapy
(n = 15). In the remaining 52 FOB-BAL-positive and 64 FOB-BAL-
negative cases (a total of 116 cases), some of the anti-infectious
treatment was withdrawn. The discontinued agents included
antibacterial (n = 75), antifungal (n = 58), anti-P. jirovecii (n = 56),
and antiviral drugs (n = 9).Table 3
Univariate analysis of factors predicting a positive FOB-BAL result
Variable OR 95% CI p-Valuea
Male 0.995 0.678–1.461 0.979
Lymphoproliferative disorder
(lymphoma, MM, CLL)
1.752 1.179–2.604 0.006
Allo SCT 0.803 0.511–1.262 0.342
Auto SCT 0.793 0.465–1.352 0.394
GVHD 1.145 0.832–1.574 0.406
Neutropenia 0.793 0.538–1.168 0.240
Fever 1.060 0.581–1.933 0.849
Cough 1.638 1.098–2.444 0.016
Dyspnea 1.477 1.007–2.164 0.046
Pleuritic pain 2.021 1.009–4.049 0.047
Hemoptysis 2.000 0.944–4.236 0.070
Number of respiratory symptoms
1 1.473 0.935–2.321 0.095
2 1.932 1.142–3.268 0.014
3 2.991 1.325–6.751 0.008
Time from symptoms to FOB, days
<4 0.656 0.260–1.653 0.372
4 0.500 0.283–0.885 0.017
FOB-BAL, ﬁberoptic bronchoscopy with bronchoalveolar lavage; OR, odds ratio; CI,
conﬁdence interval; MM, multiple myeloma; CLL, chronic lymphocytic leukemia;
Allo SCT, allogeneic stem cell transplantation; Auto SCT, autologous stem cell
transplantation; GVHD, graft-versus-host disease.
a P-value for signiﬁcance <0.05.3.5. FOB-BAL-related complications
Complications associated with FOB-BAL were rare, amounting
to 10 cases (2.4%), and included mild epistaxis (n = 2), mild
hemoptysis (n = 4), non-speciﬁc chest pain (n = 1), pulmonary
edema (n = 1), and transient self-limited respiratory decompensa-
tion (n = 2).
4. Discussion
In this large, single-center study of 425 consecutive patients
with HM and pulmonary inﬁltrates, the diagnostic yield of FOB-
BAL was found to be 51.5% (219/425). The vast majority of the
diagnosed cases were infectious (208/219, 95%), with IPA being the
most common infectious diagnosis (68%, 142/208), followed by
bacterial pneumonia (21%, 44/208), PJP (16%, 34/208), and viral
pneumonia (13%, 27/208).
The current study demonstrated a very high incidence of IPA in
the evaluated cohort compared to previous studies looking at the
diagnostic efﬁcacy of FOB-BAL in this patient population.16–18
There are a number of reasons for this ﬁnding. First, during the
study period, the Rambam Medical Center was undergoing
extensive construction and renovation, which increased the
exposure of patients to Aspergillus spp. Moreover, at that time,
anti-mold prophylaxis was not given to patients at risk of IPA.
Finally, in addition to the standard EORTC criteria, the present
study used PCR for Aspergillus DNA detection in BAL, a test that is
not employed by most other centers and was not used by the study
center 10 years earlier. The detection of Aspergillus DNA in BAL
was introduced at the study center in 2002, and its efﬁcacy was
assessed in 107 consecutive patients with HM and IPA.25 The
inclusion of PCR in the BAL evaluation for Aspergillus DNA was
found to facilitate the rapid diagnosis of IPA and even to improve
the patient outcome. This was later conﬁrmed in a meta-analysis
published in 2012.26
On the other hand, bacterial pneumonia was diagnosed at a
lower rate in the present study compared to other trials.16–18 This
could be attributed to the strict deﬁnition applied for the diagnosis
of these pathogens. Speciﬁcally, a ‘usual’ bacterial isolate from BAL
was considered the etiological agent of pneumonia only if it was
simultaneously isolated from blood, or no other pathogen was
detected. This deﬁnition was chosen for several reasons. First, in
this study, diagnostic bronchoscopy was mostly performed in
patients who had been treated empirically with broad-spectrum
antibacterial agents without improvement. Notably, in many of
these cases the bacterial isolate was susceptible to the antibiotics
the patient received. This fact led to the assumption that the
bacterial isolate from BAL was more likely to be a colonizer from
the upper airways, rather than the cause of pneumonia, in contrast
to the events with concomitant bacteremia, which indicates
invasive infection. Another reason is that at the study center, a
protective brush is not used when BAL is performed in
thrombocytopenic patients,33,34 which further increases the
probability that the bacterial isolate will be a colonizer from the
upper airways.
Similar to IPA, PJP was found in a relatively high percentage of
the patients. In addition to the gold standard method of direct
visualization of the pathogen, PCR was employed in the current
study for the detection of P. jirovecii DNA in BAL and to establish the
diagnosis of PJP. Indeed, the direct visualization was positive only
in three out of 34 patients ultimately diagnosed with PJP. The PJP
cases with positive PCR and negative smear probably did not
represent colonization, since the characteristic clinical and
radiological picture of PJP was observed in high-risk patients.
Moreover, a previous study by this study group conﬁrmed the PCR
assay to be relatively sensitive and highly speciﬁc for the detection
Figure 1. Algorithm for the investigation of patients with hematological
malignancies with persistent fever with and without respiratory symptoms.
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rate and a positive predictive value of 83%.28
In the present study, the diagnosis of CMV pneumonia was
established only in the presence of characteristic cytopathic
changes in the alveolar cells, given the fact that CMV DNA-positive
BAL could simply indicate CMV reactivation in these profoundly
immunosuppressed patients. Quantitative PCR was not employed
to diagnose pneumonia due to non-availability; this test improves
the accuracy of diagnosis and is currently recommended by
the German Society of Hematology and Medical Oncology
guidelines35.
While the deﬁnitions used in this study could have led to under-
diagnosis of bacterial and viral pneumonia, the high percentage of
these diagnoses reported in other trials may represent some over-
diagnosis.
In the current cohort of 425 consecutive patients with HM, the
diagnostic yield of FOB-BAL for the etiological diagnosis of
pulmonary inﬁltrates was 51.5%. Forty-eight percent (n = 204) of
all the patients, both with positive and negative FOB-BAL results,
underwent a modiﬁcation of the empiric treatment. A similar
study was conducted at the present study center between
2000 and 2002.15 At that time, FOB-BAL provided a speciﬁc
diagnosis for 30% of the patients and led to a change of therapy in
39% of the study group. The most common infectious etiology in
the earlier study was bacterial pneumonia (55%), followed by
fungal pneumonia (31%), viral pneumonia (12%), and PJP (2%).
These major differences in the incidence of infectious etiologies
between the two studies are most likely related to the current
implementation of novel molecular and serological diagnostic
techniques for the assessment of the BAL ﬂuid. Indeed, nowadays,
BAL ﬂuid specimens of HM patients with pulmonary inﬁltrates are
routinely evaluated using PCR for the detection of Aspergillus DNA,
P. jirovecii DNA, Legionella DNA, respiratory virus DNA, and
galactomannan antigen, while none of these was available during
the period of the previous study.
The present study did not demonstrate a superior diagnostic
yield compared to previously published trials. Hummel et al.
analyzed 249 FOB examinations and found 118 (47%) microbio-
logically documented infectious samples, 40% of which were
classiﬁed as bacterial pneumonia, and half of the diagnosed fungal
pneumonia cases appeared to be caused by Candida spp16. The
high rate of bacterial and Candida pneumonia in the latter trial
could be attributed to the liberal deﬁnitions implemented by
the authors. Shannon et al., assessing 598 infectious episodes in
HSCT recipients, reported a diagnostic yield of 55%, with most of
the cases being those of bacterial and viral (CMV)
pneumonia17. Kuehnhardt et al. analyzed 58 episodes of clinically
documented pneumonia in patients with HM or solid tumors and
found positive FOB results in 67% of cases, most of them deﬁned as
Candida pneumonia36. These trials were smaller in size, included
speciﬁc populations of hematological patients, and mainly did not
use novel molecular diagnostic techniques. The strict deﬁnitions
for bacterial, viral, and fungal pneumonia applied could plausibly
explain why a higher diagnostic yield was not reached in the
present study, despite the use of a wide range of molecular
diagnostic tests. However, the comparison of the two trials
conducted at the present study center,15 both using similar
deﬁnitions but only one employing PCR for the identiﬁcation of
speciﬁc pathogens, revealed a signiﬁcant superiority of the
present study in the diagnostic yield reached (51.5% vs. 30.4%,
p < 0.01).
In the current study, the prompt performance of FOB-BAL after
the development of a clinical respiratory picture provided an
increased yield of the procedure. This ﬁnding is in consensus with
prior reports,17,37 documenting a signiﬁcantly improved diagnostic
yield in FOB-BAL performed within the ﬁrst 4 days sincepresentation, compared to the procedures performed at a later
time point.
The likelihood of a positive FOB-BAL appears to be higher in HM
patients presenting with respiratory symptoms or complaints. This
association, also observed in smaller studies,38 may be explained
by a high burden of pathogens responsible for the overwhelming
clinical presentation, before broad-spectrum empiric treatment is
started. Notably, patients with lymphoproliferative malignancies,
often presenting with profound lymphopenia, had a higher
likelihood of a positive FOB-BAL result compared to those
diagnosed with acute leukemia. This ﬁnding may reﬂect the high
proportion of PJP in this population, where the diagnosis is mainly
established using molecular techniques.39 Another explanation
could be the fact that the majority of patients with lymphopro-
liferative malignancies were not exposed to antibiotics (either
prophylactic or therapeutic) at the time of developing the
infection, whereas patients with acute leukemia had been
hospitalized previously and treated with broad-spectrum anti-
biotics for neutropenic fever.
In summary, this large single-center study conﬁrms FOB-BAL to
be safe and effective in determining the etiology of pulmonary
inﬁltrates in HM patients. The routine use of novel molecular and
serological techniques in the assessment of BAL ﬂuid (Figure 1),
contributes to a rapid and precise detection of life-threatening
infections and may allow targeted treatment to be provided to this
patient population.
Conﬂict of interest/funding: None.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.ijid.2016.07.011.
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